Celyad Oncology SA
XBRU:CYAD

Watchlist Manager
Celyad Oncology SA Logo
Celyad Oncology SA
XBRU:CYAD
Watchlist
Price: 0.682 EUR 1.79% Market Closed
Market Cap: 28.3m EUR
Have any thoughts about
Celyad Oncology SA?
Write Note

P/E
Price to Earnings

-3.6
Current
-1.5
Median
21.3
Industry
Lower than median
Lower than industry value

Price to Earnings (P/E) ratio is a valuation multiple that compares a company’s market capitalization to its net income. It indicates the dollar amount an investor can expect to invest in a company in order to receive $1 of that company’s earnings.

P/E
-3.6
=
Market Cap
28.3m EUR
/
Net Income
-7.8m EUR
All Countries
Close
Market Cap P/E
BE
Celyad Oncology SA
XBRU:CYAD
28.3m EUR -3.6
FR
Pharnext SCA
OTC:PNEXF
6T USD -182 946.5
US
Abbvie Inc
NYSE:ABBV
320.5B USD 63.1
US
Amgen Inc
NASDAQ:AMGN
140.8B USD 33.3
US
Gilead Sciences Inc
NASDAQ:GILD
114.4B USD 907.6
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
105.4B USD -219.7
US
Epizyme Inc
F:EPE
94.1B EUR -467
AU
CSL Ltd
ASX:CSL
137B AUD 32.2
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
79.4B USD 17.1
US
Seagen Inc
F:SGT
39.3B EUR -54.1
NL
argenx SE
XBRU:ARGX
36.5B EUR -333.5
Earnings Growth PEG
BE
Celyad Oncology SA
XBRU:CYAD
Average P/E: 210.7
Negative Multiple: -3.6
N/A N/A
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -182 946.5 N/A N/A
US
Abbvie Inc
NYSE:ABBV
63.1
72%
0.9
US
Amgen Inc
NASDAQ:AMGN
33.3
20%
1.7
US
Gilead Sciences Inc
NASDAQ:GILD
907.6
21%
43.2
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
Negative Multiple: -219.7
14%
N/A
US
E
Epizyme Inc
F:EPE
Negative Multiple: -467 N/A N/A
AU
CSL Ltd
ASX:CSL
32.2
18%
1.8
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
17.1
13%
1.3
US
S
Seagen Inc
F:SGT
Negative Multiple: -54.1 N/A N/A
NL
argenx SE
XBRU:ARGX
Negative Multiple: -333.5 N/A N/A

P/E Forward Multiples

Forward P/E multiple is a version of the P/E ratio that uses forecasted net income for the P/E calculation. 1-Year, 2-Years, and 3-Years forwards use net income forecasts for 1, 2, and 3 years ahead, respectively.

1-Year Forward
P/E
N/A
2-Years Forward
P/E
N/A
3-Years Forward
P/E
N/A